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Neonatal Seizures
Faye S. Silverstein, MD,1 and Frances E. Jensen, MD2
In childhood, the risk for seizures is greatest in the neonatal period. Currently used therapies have limited efficacy. Although the
treatment of neonatal seizures has not significantly changed in the past several decades, there has been substantial progress in
understanding developmental mechanisms that influence seizure generation and responsiveness to anticonvulsants. This review
includes an overview of current approaches to the diagnosis and treatment of neonatal seizures, identifies some of the critical
factors that have limited progress, and highlights recent insights about the pathophysiology of neonatal seizures that may provide
the foundation for better treatment.
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In childhood, the risk for seizures is greatest in the
neonatal period (1.8–3.5/1,000 live births in the
United States). Available data indicate that phenobar-
bital remains the first-line therapy for treatment of
neonatal seizures.1 Yet, a recent Cochrane Review con-
cluded that “there is little evidence…to support the use
of any of the anticonvulsants currently used in the neo-
natal period.”2
Although there has been little recent progress in the
effective treatment of neonatal seizures,3,4 there have
been substantial advances regarding understanding
pathophysiology and, in particular, developmental
stage–specific factors that influence mechanisms of sei-
zure generation, responsiveness to anticonvulsants, and
the impact on central nervous system integrity.
Many factors are responsible for the lack of progress
in neonatal seizure therapeutics. Rigorous studies have
confirmed clinical impressions that the older anticon-
vulsants have only limited efficacy in neonates (dis-
cussed later). To date, no novel compounds have been
developed specifically for treatment of neonatal sei-
zures. Other challenges inherent in improving the
treatment and outcome of neonatal seizures include
the diverse causative factors and comorbidities, and
the complexities of seizure diagnosis. Neonates dis-
play behaviors that mimic seizures, and electrographic
seizures with no clear-cut clinical manifestations
(“electroclinical dissociation”) are common in neo-
nates. There is consensus that some type of electro-
physiological monitoring is essential to confirm the
diagnosis of seizures and assess the efficacy of treat-
ment in neonates. It is currently uncertain whether
available cortical function monitors (amplitude-
integrated electroencephalographic [EEG] devices)
and simplified EEG systems are adequate for seizure
detection, and this is an area of active research.
Moreover, experimental data have raised concerns
about the potential adverse effects on brain develop-
ment of currently used (and only modestly effective)
anticonvulsants in neonates. The availability of new
therapeutic agents has generated substantial optimism
that safer and more effective treatment of neonatal sei-
zures is feasible.
In this review, we highlight both areas in which sub-
stantial progress has been made, and identify the most
important unanswered questions about the pathophys-
iology and treatment of seizures in neonates. We rec-
ommend consultation of reference texts for details re-
garding differential diagnosis, currently recommended
diagnostic evaluation, and treatment of neonatal sei-
zures.5,6
Clinical Overview
Several features distinguish seizures in neonates from
those in older children. Neonatal seizures are often be-
haviorally subtle, and the EEG pattern often reflects a
multifocal process, rather than coordinated seizure ac-
tivity. In addition, diagnosis is complicated by the fact
that neonates may display stereotyped repetitive rhyth-
mic movements that would not be conventionally clas-
sified as seizures because they lack an EEG correlate.
Whether such episodes, which are most commonly ob-
served in encephalopathic infants, represent subcorti-
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cally generated seizures and whether they should be
treated with anticonvulsants are unresolved questions.
In neonates, single seizures are unusual, and recur-
rence is expected without treatment. A specific cause
can be identified much more commonly than in older
children. The underlying cause of seizures is a signifi-
cant determinant of neurological outcome, and this has
resulted in some skepticism about the potential positive
impact of effective anticonvulsant therapy on neurode-
velopmental outcome.
Diagnosis
The electrographic features of neonatal seizures are also
distinctive, and interpretation of neonatal EEG results
is often particularly challenging.5 In view of the more
subtle electrographic features of ictal events in neo-
nates, a burst duration of 10 seconds (vs 3 seconds in
older age groups) is required to diagnose an electro-
graphic seizure. There is no consensus about the defi-
nition of status epilepticus in neonates. One opera-
tional definition suggested, based on EEG criteria, is
that more than 50% of the EEG analyzed demon-
strates on-going seizures,7 and it is generally defined as
30 minutes of ongoing seizures.8
Investigators have incorporated video-EEG analysis
to correlate behavioral events with electrographic sei-
zures. Mizrahi and Kellaway9 found that focal clonic
seizures, some forms of myoclonic seizures, and focal
tonic seizures were most consistently associated with
electrical seizure activity, whereas most “subtle” sei-
zures, all generalized tonic seizures, and some forms of
myoclonic seizures were either not associated with
EEG seizure activity or had an inconsistent relationship
with such activity. Seizures that were consistently and
coherently related to focal EEG seizure activity had a
high correlation with focal brain lesions and a favorable
short-term outcome. Seizures with no relationship or
an inconsistent relationship to EEG seizure activity
were correlated with diffuse processes such as hypoxic-
ischemic encephalopathy and a poor short-term out-
come.
In view of this diagnostic complexity, some experts
argue that the diagnosis of neonatal seizures cannot/
should not be based on clinical observation alone;
however, in most neonatal intensive care units (ICUs),
EEGs are not immediately available, and the initial di-
agnosis and treatment of seizures are currently based on
clinical observation and assessment. In clinical practice,
EEGs are often ordered after administration of antiepi-
leptic drugs (AEDs). In contrast, with clinical practice
in older age groups, a full loading dose of an AED
(most commonly phenobarbital; see later) is adminis-
tered quickly after a single seizure is diagnosed because
of anticipated seizure recurrence. A relatively common
trend in encephalopathic neonates with seizures is the
persistence of electrographic seizures after initiation of
AED therapy. There is no agreement about optimal
treatment in this setting.10
An important emerging change in clinical practice is
the utilization of amplitude-integrated EEG devices in
neonatal ICUs. These devices, which permit concurrent
visualization of raw EEG tracings, were initially applied
to assess cerebral functional integrity (amplitude, fre-
quency); however, amplitude-integrated EEG patterns
suggestive of seizures are recognized by experienced ob-
servers, and new algorithms (proprietary) for automated
seizure detection are available. Whether this type of
“brain monitoring,” which could increase the recogni-
tion (and treatment) of subtle seizures, will improve
neurodevelopmental outcome is unknown. Ongoing
studies are comparing the accuracy and sensitivity of
amplitude-integrated EEG or other limited montages
and conventional EEG for seizure detection.11–13
Causative Factors
The neonatal period (the first 28 days of life) has the
greatest incidence of seizures across the life span at 1.8
to 3.5 per 1,000 live births.14–16 The most common
cause of neonatal seizures is hypoxic-ischemic enceph-
alopathy, which occurs in approximately 1 to 2 per
1,000 live births.17–19 In the neonate, a broad range of
systemic and central nervous system disorders can in-
crease the risk for seizures (Table). Assessment of cause
and initial treatment typically occur concurrently. The
highest priority is identification of treatable systemic
causes of seizures, including metabolic derangements
(hypoglycemia, hypocalcemia, hypomagnesemia) and
infection. The predominant cause is to some degree de-
pendent on the setting. In a recently reported study
from a tertiary care referral neonatal ICU, about two-
thirds were associated with hypoxic-ischemic encepha-
lopathy or cerebrovascular disorders.20
Although the term infant is at high risk for seizures, it
is increasingly recognized that seizures can be a signifi-
cant problem in preterm infants. A recent population-
based cohort of very-low-birth-weight infants in Israel
reported an overall incidence of neonatal seizures of
5.6%. Younger gestational age, male sex, and major sys-
temic (eg, sepsis) and neurological comorbidities (eg, in-
traventricular hemorrhage or periventricular leukomala-
cia) were all independent predictors of neonatal
seizures.21,22
Infants with neonatal encephalopathy as a result of
hypoxia-ischemia are at particularly high risk for sei-
zures. In two recent clinical trials of hypothermia for
treatment of neonatal hypoxic-ischemic encephalopa-
thy, seizures were frequent at the time of random-
ization (40 – 60%).23,24 Cerebrovascular disorders
including arterial and venous stroke, intracerebral hem-
orrhage, and subarachnoid hemorrhage also frequently
present clinically with seizures. Thus, brain imaging is
an essential component of the diagnostic evaluation,
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and magnetic resonance imaging is gaining acceptance
as the optimal neuroimaging modality. Infants with
complex congenital heart disease are at high risk for
seizures in the perioperative period.25 Other less com-
mon causes of neonatal seizures include developmental
abnormalities, inborn errors of metabolism, and other
genetic syndromes that are cited in the Table and dis-
cussed in detail in reference texts.5,6
Prognosis
One of the first studies of the prognosis of neonatal sei-
zures was a review of 277 newborns with seizures en-
rolled in the Collaborative Perinatal Project (data col-
lected about 50 years ago). In this group, there was 35%
mortality, and 30% of survivors had adverse neurologi-
cal outcomes at age 7 years, including cerebral palsy
(13%), intelligence quotient less than 70 (19%), and ep-
ilepsy (20%), alone or in combination.26 In a recent
study of 89 term infants with clinical seizures, there was
markedly less neonatal mortality (7%), but a remarkably
similar degree of poor long-term neurological outcome
in 28%.20 Analysis of risk factors in the latter study
demonstrated a strong association between seizure cause
and outcome; cerebral dysgenesis and global hypoxia-
ischemia were associated with poor outcome. Normal
neonatal/early infancy neurological examination and
normal/mildly abnormal neonatal EEG were associated
with a favorable outcome, particularly if neonatal neu-
roimaging was normal. Indeed, the burden of electro-
graphic seizures correlates with poor outcome.27
Some of the therapeutic nihilism regarding a rationale
for aggressive treatment of neonatal seizures stems from
observations that the underlying cause is a major deter-
minant both of medical “refractoriness” and of neurode-
velopmental outcome. Yet, there is evidence to suggest
that the deleterious effects of seizures may be most pro-
nounced in the setting of underlying hypoxic-ischemic
brain injury. An intriguing study of neonates with severe
hypoxic-ischemic encephalopathy (which has not been
replicated) reported better outcome at age 3 after neo-
natal treatment with phenobarbital (40mg/kg).28
Mechanisms that could account for seizure-induced
amplification of ischemic injury include increases in
brain temperature and metabolic demands, generation
of mediators (such as reactive oxygen species) that con-
tribute to tissue damage, and disruption of endogenous
protection and repair mechanisms. Important data
were provided by a study that used magnetic resonance
spectroscopy to evaluate brain metabolism and integ-
rity in neonates with asphyxia and seizures.29 This
analysis demonstrated that seizures contributed to ab-
normal metabolism (as measured by the lactate/choline
ratio) and tissue injury (as measured by the N-acetylas-
partate/choline ratio).






Withdrawal syndromes associated with maternal drug use
Iatrogenic associated with inadvertent fetal administration of local anesthetic
Rare inborn errors of metabolism (including pyridoxine responsive)
Cerebrovascular










Multiple forms of cerebral dysgenesis
Hypoxic-ischemic encephalopathy
Rare genetic syndromic disorders
Benign neonatal familial convulsions (sodium and potassium channel mutations identified)
Early myoclonic encephalopathy
This is not an exhaustive list, but rather is intended to illustrate the diversity of causative factors encountered in this population.
114 Annals of Neurology Vol 62 No 2 August 2007
Antiepileptic Drug Therapy
Rigorous evaluation of the efficacy of AED therapy in
neonates is difficult. In view of the challenges inherent
in behavioral diagnosis, incorporation of continuous
EEG monitoring represents the gold standard for stud-
ies of therapeutic efficacy.
There is consensus that currently used anticonvul-
sants are often ineffective for treatment of neonatal sei-
zures.3 Painter and colleagues’30 classic study reported
that in term infants with EEG-confirmed seizures,
loading doses of phenobarbital and phenytoin were
equally but incompletely effective, and that either drug
alone controlled seizures in fewer than half. Variable
efficacy (ranging from minimal to 100%) has been re-
ported for midazolam as a second-line medication.31,32
Lidocaine is an effective treatment for refractory neo-
natal seizures, but concerns about cardiac toxicity have
limited widespread adoption of this agent.33 An equally
important question about AED therapy in neonates is
whether chronic therapy is warranted after successful
treatment of seizures. In encephalopathic infants, sei-
zures often wane abruptly by the end of the first week
of life; although it is unknown whether continuation of
AED therapy is of benefit, this practice is quite com-
mon.1 Clinical studies of early-life anticonvulsant treat-
ment on cognitive and neurological development are
invariably confounded by the multiple underlying
causes of neonatal seizures, and it will be essential to
develop comprehensive strategies for delineation of rela-
tively homogeneous clinical populations for such studies.
Pathophysiology of Neonatal Seizures
Developmental stage–specific mechanisms influence the
generation of seizures, the impact of seizures on brain
structure and function, intrinsic adaptive responses
mechanisms, and the impact of anticonvulsant therapy.
We highlight advances in three important areas: devel-
opmental regulation of factors governing neuronal excit-
ability (neurotransmitters and receptors, ion homeosta-
sis), studies in animal models of neonatal seizures, and
developmental stage–specific effects of anticonvulsants.
An important rationale for studies of these distinctive
developmental mechanisms is that they should provide
important clues for the age-specific therapy.
Factors Governing Neuronal Excitability
Multiple factors conspire to enhance synaptic excita-
tion in the neonatal brain. Indeed, in humans, synapse
and dendritic spine density are both peaking around
birth and into the first months of life.34–36 Consider-
able experimental data implicate developmental
changes in the major central nervous system excitatory
class of glutamate neurotransmitter receptors and those
of the major inhibitory class of -amino butyric acid
(GABA) receptors as pivotal mechanisms that underlie
the greater susceptibility of the immature brain to sei-
zures.37,38 There is abundant evidence from animal
models and human tissue studies that neurotransmitter
receptors are highly developmentally regulated (Fig).
Glutamate receptors are critical for plasticity and
are transiently overexpressed during development
compared with adulthood. A relative overexpression
of certain glutamate receptor subtypes in both rodent
and human developing cortex coincides with ages of
increased seizure susceptibility (see Fig).37,39 – 41 Yet,
the extent to which specific glutamate receptors con-
tribute to increased susceptibility to seizures in neo-
nates is currently unclear. Glutamate receptors in-
clude both ligand-gated ion channels, permeable to
sodium, potassium, and in some cases calcium, and
metabotropic subtypes.42,43 They are localized both
to synapses and nonsynaptic sites on neurons, and are
also expressed on glia. The ionotropic receptor sub-
types are classified based on selective activation by
specific ligands, N-methyl-D-aspartate (NMDA),
-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA), and kainate.
NMDA receptors are heteromeric, including an ob-
ligate NR1 subunit, and their makeup is developmen-
tally regulated. In the immature brain, the predomi-
nant NR2 subunit is the NR2B subunit, which
Fig. Schematic depiction of maturational changes in glutamate
and GABA receptor expression and function in the developing
brain. Developmental pattern for rat (top x-axis) and human
(bottom x-axis) are shown, based on recent literature.37,39,40,69
GABA receptors are depolarizing (light blue line) early in the
first postnatal week in the rat and up to and including the
neonatal period in the human, whereas functional inhibition
(black line) is gradually reached over development.69 Before
full maturation of GABA-mediated inhibition, the N-methyl-
D-aspartate (NMDA; dark blue line) and -amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA; orange
line) subtypes of glutamate receptors peak between the first
and second postnatal weeks in the rat and in the neonatal
period in the human. Kainate receptor binding (green line) is
initially low and gradually increases to adult levels by the
fourth postnatal week.94
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functionally results in longer current decay time com-
pared with the NR2A subunit, which is highly ex-
pressed on mature neurons. Other developmentally
regulated subunits of functional relevance include the
NR2C, NR2D, and NR3A subunits that are increased
in the first two postnatal weeks (in rodent brain) and
the presence of which results in reduced magnesium
sensitivity, resulting in increased excitability.42,44 Al-
though this receptor may represent an age-specific ther-
apeutic target, pharmacological strategies based on
NMDA antagonism may inevitably be limited by the
central roles that NMDA receptor activation plays in
learning, memory, and brain development.45,46 How-
ever, future clinically applicable NMDA antagonist
strategies would ideally target more specific down-
stream pathways that differentiate pathological from
physiological actions.
The AMPA subtype of glutamate receptor is thought
to subserve most fast excitatory synaptic transmission,
and in the adult, most AMPA receptors are not cal-
cium permeable. AMPA receptors are heteromeric and
made up of four subunits, including combinations of
the GluR1, GluR2, GluR3, or GluR4 subunits.42
However, in the immature rodent and human brain,
AMPA receptors are calcium permeable because they
lack the GluR2 subunit.41,47 AMPA receptor subunits
are also developmentally regulated, with GluR2 ex-
pressed only at low levels until the third postnatal week
in rodents and later in the first year of life in the hu-
man cortex.39,40 Hence, both NMDA and AMPA re-
ceptors are expressed at levels and with subunit com-
position that enhances excitability of neuronal
networks around term in the human and in the first
two postnatal weeks in the rodent. Indeed, this age
window around term is the period of greatest incidence
of seizures across the life span in the human,48,49 and
similarly, in the rodent, seizure susceptibility peaks in
the second postnatal week in many models.37,50
Studies in Animal Models of Neonatal Seizures
The majority of recent in vivo animal studies of neo-
natal seizures have been performed in rodent models.
Limitations shared by all models include both the chal-
lenges inherent in precise correlation of developmental
stage between neonatal rodents and humans, and accu-
rate modeling of clinical disorders such as hypoxic-
ischemic encephalopathy.
In immature rodent models of hypoxia-induced sei-
zures, seizures are relatively refractory to GABA recep-
tor agonist therapy.37 However, the AMPA receptor
antagonists such as NBQX and topiramate blocked the
acute seizures and long-term sequelae in this mod-
el.51–53 In addition, topiramate in combination with
hypothermia markedly attenuates neonatal hypoxic-
ischemic injury in the neonatal rodent.54 These find-
ings are of particular relevance in that hypoxic-ischemic
encephalopathy is one of the most common causes of
seizures in neonates.20,55 In addition to the clinical ev-
idence cited earlier, there is also experimental evidence
that seizures generated during hypoxia contribute to
hypoxia-induced neuronal damage,56 and that preven-
tion and adequate treatment of seizures delay the onset
of anoxic depolarization, and thereby ameliorate the
neurological outcome after brain hypoxia in the new-
born.57 In a complementary model, Yager and col-
leagues58 found that kainate-induced seizures amplified
hypoxic-ischemic brain injury in a neonatal rat model.
Of particular interest and potential clinical relevance
was the finding that prevention of seizure-induced hy-
perthermia was protective59; these findings suggested
that seizure-induced increases in brain temperature
could underlie their deleterious effects in this setting.
In a sheep model of perinatal asphyxia, the neuropro-
tective efficacy of hypothermia was lost when treatment
was initiated after the onset of seizures.60
Few studies have addressed the efficacy of NMDA
receptor antagonists in models of infantile or early-life
seizures. The NMDA receptor antagonists MK801 and
memantine are neuroprotective in neonatal hypoxic-
ischemic injury models. However, MK801 had no
seizure-suppressing efficacy in the rat hypoxic seizure
model,51 and pretreatment with MK801 surprisingly
enhanced the seizure severity in early-life seizures in-
duced by the chemoconvulsant kainate.61
Expression and function of the inhibitory GABAA
receptors are also developmentally regulated. Rodent
studies show that GABA receptor binding, synthetic
enzymes, and overall receptor expression are lower in
early life compared with later.37,62 GABA receptor
function is regulated by subunit composition, and the
4 and 2 subunits are relatively overexpressed in the
immature brain compared with the 1 subunit.63 No-
tably, when the 4 subunit is expressed, the receptor is
less sensitive to benzodiazepines compared with recep-
tors containing 1,64 and as is often the case clinically,
seizures in the immature rat respond poorly to benzo-
diazepines.51,65
Receptor expression and subunit composition can
partially explain the resistance of seizures in the imma-
ture brain to conventional AEDs that act as GABA
agonists. However, inhibition of neuronal excitability
via GABA agonists relies on the ability of GABAA re-
ceptors to cause a net influx of chloride (Cl) from the
neuron, resulting in hyperpolarization.57 In immature
forebrain, GABA receptor activation can cause depolar-
ization rather than hyperpolarization.66–68 GABAA-
mediated depolarization occurs because the Cl gradi-
ent is reversed in the immature brain: Cl levels are
high in the immature brain because of a relative un-
derexpression of the Cl exporter KCC2 compared
with mature brain (see Fig).69 Recent studies in human
brain have shown that KCC2 is virtually absent in cor-
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tical neurons until late in the first year of life, and
gradually increases thereafter, whereas the Cl im-
porter NKCC1 is overexpressed both in the neonatal
human brain and during early life in the rat when sei-
zures are resistant to GABAA agonists.
69 The NKCC1
inhibitor, bumetanide, shows efficacy against kainate-
induced seizures in the immature brain, suggesting that
this agent, already Food and Drug Administration ap-
proved as a diuretic, may be clinically useful in treat-
ment of neonatal seizures.
In addition to those noted earlier, multiple animal
models of neonatal and early-life seizures show a simi-
lar resistance to conventional AEDs. These include sei-
zures induced by systemically administered convul-
sants, such as kainate, pentylentrazol, flurothyl, and
pilocarpine, and those administered intracerebrally, in-
cluding tetanus toxin and kainate.70 It is widely ob-
served that prolonged seizures and status in the imma-
ture rodent cause only minimal neuronal injury, in
contrast with often extensive hippocampal and limbic
injury in the adult rodent brain.71,72
In the past, this relative lack of detectable neuronal
injury was interpreted as evidence that the immature
brain was resistant to harmful effects of seizures. Yet,
early studies in neonatal rats showed that flurothyl-
induced seizures resulted in reduced brain growth and
DNA synthesis.73 More recent experimental data dem-
onstrate significant long-term adverse consequences of
seizures and status epilepticus in the immature brain.
These include increases in seizure susceptibility in later
life,74–77 as well as permanent impairments in learning,
memory, and cognition.78,79 These adverse outcomes
are not related to seizure-induced neuronal death but
are attributable to altered neuronal connectivity80 and
receptor expression.41,81,82 These studies suggest that
the impact of seizure on the developing brain is qual-
itatively different from that in the adult.
The immature brain is an ideal substrate in which to
study epileptogenesis and the effect of seizures on syn-
aptic and network function during the developmental
period when synaptogenesis and neuronal network ex-
pansion are robust.37,83 Many models demonstrate that
neonatal seizures alter synaptic plasticity,70 and recent
studies are delineating the molecular signaling cascades
that are altered after early-life seizures.82,84 Such infor-
mation may identify seizure-induced therapeutic targets
that will lead to strategies for disease modification,
rather than simply anticonvulsant control.
Anticonvulsants and the Developing Brain
Emerging identification of age-specific mechanisms for
neonatal seizures is pointing to the use of novel thera-
peutic targets. Caution must be exercised when devis-
ing new therapies because the target may indeed be es-
sential for normal brain development, albeit a
contributor to neuronal hyperexcitability.
More than two decades ago, experimental data
emerged demonstrating that phenobarbital exposure
had adverse effects on survival and morphology of cul-
tured neurons, derived from fetal mouse tissue, and
these observations raised concerns about risks of this
drug for treatment of neonatal seizures.85,86 Subse-
quent studies in neonatal rats demonstrated that daily
treatment with phenobarbital or diazepam in the first
postnatal month resulted in measurable changes in re-
gional cerebral metabolism and behavior.87,88
More recently, evidence emerged that brief systemic
treatment with conventional AEDs such as phenobar-
bital, diazepam, phenytoin, and valproate all increase
apoptotic neuronal death in normal immature ro-
dents.89 Similarly, NMDA receptor antagonists also in-
duce an increase in constitutive apoptosis in the devel-
oping rodent brain.90 Yet, the AMPA receptor
antagonists NBQX and topiramate do not cause such
adverse effects,90,91 although the mechanism for this
relative safety over the other agents is not understood.
The novel AED levetiracetam also has no effect on ap-
optosis in the developing brain.92
Despite these data on adverse effects or lack thereof
in rodents, no evidence of similar phenomena exists for
other species, and it remains unknown whether these
toxicity mechanisms are relevant for human neonates.
Moreover, interpretation of AED toxicity studies must
be tempered by the consideration that these experi-
ments are typically performed in normal animals, and
that the impact of AED administration may well differ
in normal animals and in those with seizures.
Future Directions
Refractory neonatal seizures remain a significant clini-
cal problem, and no new treatments for this condition
have been introduced for decades. There will certainly
be opportunities to perform therapeutic trials of new
agents with well-defined clinical outcome measures.
Systematic clinical evaluation of safety and pharmaco-
kinetics in the appropriate study populations must pre-
cede analysis of efficacy, and this is particularly chal-
lenging in neonates. Interdisciplinary collaboration
between neonatologists and neonatal neurologists is es-
sential for the success of such studies.
As basic research demonstrates new age-specific ther-
apeutic targets, these targets can be validated with anal-
ysis of cell-specific gene and protein expression in hu-
man autopsy samples. Although the experimental data
regarding the potential efficacy of agents such as bu-
metanide, topiramate, and levetiracetam are encourag-
ing, the duration of use of these agents may be limited
by safety concerns related to their effects on long-term
brain development. Animal model trials and human
studies must be aligned to understand how safety and
efficacy data from rodent and nonhuman primates pre-
dict human responses. A number of early-life seizure
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models exist in which there are indeed long-term ef-
fects on learning, and these could also be used to ad-
dress the effects of treatment on brain and cognitive
development.
Clinical research is evolving to include new methods
for seizure detection in the newborn. There is no
widely approved consensus regarding optimal “stan-
dard” lead montage for EEG monitoring such as that
which exists for older children and adults,11,12 and
unique logistical factors suggest that fewer leads may be
more clinically appropriate. There is considerable en-
thusiasm for introduction of amplitude-integrated EEG
devices into neonatal ICUs, although their sensitivity
and specificity for seizure detection remain uncer-
tain.11,93 Clinical therapeutic trials in neonates would
be greatly improved if there were accurate biomarkers
of acute and chronic therapeutic efficacy, yet none ex-
ists other than the EEG. Measures of brain metabolic
integrity such as magnetic resonance spectroscopy or
near-infrared spectroscopy, when combined with EEG
data, may provide surrogate measures of treatment ef-
ficacy.
Although it is clear that there are emerging technol-
ogies and therapeutic strategies available for study in
neonatal seizures, there are many practical challenges
that must be addressed to implement clinical trials of
new AEDs in neonates. Incorporation of continuous
EEG monitoring into clinical studies of neonatal sei-
zure therapy is a daunting task. Delineation of reason-
ably homogeneous clinical populations for study
and/or practical stratification strategies that take into
account the critical factors that contribute to outcome,
including gestational age, seizure cause, and systemic
disorders, and their treatments are essential prerequi-
sites for trials of anticonvulsant efficacy, as well as neu-
rological outcomes. It will also be essential to assess
AED interactions with other therapies (eg, induced hy-
pothermia) in critically ill infants.
Recent surveys of neurologists and neonatologists
(F.S.S., unpublished data) suggest that the majority of
physicians who treat neonatal seizures do not think
that a study designed with a placebo-treated or
delayed-treatment control group is ethically justifiable
or feasible currently. A substantial majority support a
study design with randomization for an add-on drug
study (with varying entry criteria). Seizure cessation is
an important therapeutic goal; yet, improved neurode-
velopmental outcome is clearly of critical importance.
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